指南与共识治疗药物监测与药物基因组学药物不良反应与药物警戒

CPIC指南:CYP2C9与非甾体抗炎药

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
指南 / 共识 · Clin Pharmacol Ther · 2020-04-28

CPIC发布指南,基于CYP2C9基因型为NSAIDs提供治疗推荐。CYP2C9多态性影响多种NSAIDs的代谢与清除,改变药物暴露并可能影响安全性。指南汇总文献证据并给出基因型指导的用药建议。

要点

  • CYP2C9多态性影响多种NSAIDs的代谢和清除,改变药物暴露。
  • 指南基于CYP2C9基因型为NSAIDs提供治疗推荐。
  • NSAIDs可导致严重胃肠、肾和心血管不良事件。

核心结论

  • CYP2C9基因型影响多种NSAIDs的代谢与清除,进而影响药物暴露和潜在安全性。

研究设计与样本

  • CPIC制定指南,汇总已发表文献证据,为NSAIDs提供基于CYP2C9基因型的治疗推荐。

主要发现

  • CYP2C9多态性影响该类中多种药物的代谢和清除,从而影响药物暴露和潜在安全性。

临床怎么用

  • 临床可依据CYP2C9基因型为患者选择或调整NSAIDs治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020. PMID: 32189324. doi:10.1002/cpt.1830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。